Imfinzi + Imjudo approved in US for lung cancer
11 November 2022 07:00 GMT Imfinzi and Imjudo with chemotherapy approved in the US for patients with metastatic non-small cell lung cancer Approval based on POSEIDON Phase III trial results, which showed significant survival benefit with a limited course of Imjudo added to Imfinzi and chemotherapy AstraZeneca's Imfinzi (durvalumab) in combination with Imjudo (tremelimumab) plus platinum-based chemotherapy has been approved in the US for the treatment of adult patients with Stage IV (metastatic) non-small cell lung cancer (NSCLC). The approval by the Food and Drug